Biopharmaceutical company Onconova Therapeutics, Inc. (ONTX) said Monday that INSPIRE, the company's pivotal Phase 3 study assessing the efficacy and safety of IV rigosertib in higher-risk myelodysplastic syndromes (MDS) or HR-MDS patients, did not meet its primary endpoint of improved survival.
from RTT - Biotech https://ift.tt/3gt7SFs
via IFTTT
No comments:
Post a Comment